• Home
  • About Us
  • Contact Us
  • Privacy Policy
  • Special Offers
Business Intelligence Info
  • Business Intelligence
    • BI News and Info
    • Big Data
    • Mobile and Cloud
    • Self-Service BI
  • CRM
    • CRM News and Info
    • InfusionSoft
    • Microsoft Dynamics CRM
    • NetSuite
    • OnContact
    • Salesforce
    • Workbooks
  • Data Mining
    • Pentaho
    • Sisense
    • Tableau
    • TIBCO Spotfire
  • Data Warehousing
    • DWH News and Info
    • IBM DB2
    • Microsoft SQL Server
    • Oracle
    • Teradata
  • Predictive Analytics
    • FICO
    • KNIME
    • Mathematica
    • Matlab
    • Minitab
    • RapidMiner
    • Revolution
    • SAP
    • SAS/SPSS
  • Humor

IBM uses AI to evaluate risk of developing genetic diseases

August 20, 2020   Big Data
 IBM uses AI to evaluate risk of developing genetic diseases

Automation and Jobs

Read our latest special issue.

Open Now

In a study published in the journal Nature Communications, scientists at IBM, the Broad Institute of MIT and Harvard, and health tech company Color find evidence that the presence of genetic mutations isn’t a reliable precursor to genetic diseases. They claim diseases can be so greatly influenced by other factors that the risk in carriers is sometimes as low as in that of noncarriers.

The research — which stems from a larger, three-year collaboration between IBM Research and the Broad Institute that was announced in 2019 — aims to support clinicians leveraging data to better identify patients at serious risk for conditions like cardiovascular disease. Insights could be useful in making health care and prevention decisions, helping clinicians choose whether to recommend imaging or more drastic, surgical interventions, like mastectomies.

In the course of the study, an IBM-led team developed models that analyze a person’s genetic risk factors, clinical health records, and biomarker data to more accurately predict the onset of conditions like heart attacks, sudden cardiac death, and atrial fibrillation. With Color, the researchers investigated whether polygenic background — the variants and factors within an individual’s genome — could influence the occurrence of disease in genomic conditions such as familial hypercholesterolemia, hereditary breast and ovarian cancer, and Lynch syndrome.

The coauthors analyzed de-identified records from over 80,000 patients across two large data sets, the UK Biobank and Color’s own. Among carriers of a monogenic risk variant, they identified “substantial variations” in risk based on polygenic background, implying carriers don’t always develop diseases. For example, the probability of developing coronary artery disease (CAD) by age 75 ranged from 17.5% to 77.9% for carriers of familial hypercholesterolemia. For comparison, CAD prevalence among noncarriers ranged from 13% if they had a low-risk polygenic score to 41% with a high-risk score.

“By leveraging large databases to combine and analyze medical and genomic data from tens of thousands of people, we have been able to shed significant new light on a number of serious, chronic diseases,” IBM Research principal scientist and coauthor Kenney Ng said. “Ultimately, our findings unveil a silver lining: Even if an individual carries a genetic mutation associated with one of these diseases, their absolute risk might not be as set in stone as previously thought. In fact, their absolute risk might be nearly equivalent to an individual who doesn’t carry the mutation at all — depending on other factors and mutations within their specific genome.”

IBM says future work will include investigating ways genomics, clinical data, and AI can be harnessed to develop new tools that offer health professionals insight into disease risk. The goal is to build algorithms that accurately indicate a predisposition to a health condition and make those tools available — including methods to calculate an individual’s risk of disease based on variants in a genome.

IBM previously collaborated with the Broad Institute in 2016. As part of a five-year project, the company sought to help researchers using AI and genomics better understand how cancers become resistant to therapies.

Let’s block ads! (Why?)

Big Data – VentureBeat

Developing, diseases, evaluate, Genetic, Risk, Uses
  • Recent Posts

    • Accelerate Your Data Strategies and Investments to Stay Competitive in the Banking Sector
    • SQL Server Security – Fixed server and database roles
    • Teradata Named a Leader in Cloud Data Warehouse Evaluation by Independent Research Firm
    • Derivative of a norm
    • TODAY’S OPEN THREAD
  • Categories

  • Archives

    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018
    • December 2017
    • November 2017
    • October 2017
    • September 2017
    • August 2017
    • July 2017
    • June 2017
    • May 2017
    • April 2017
    • March 2017
    • February 2017
    • January 2017
    • December 2016
    • November 2016
    • October 2016
    • September 2016
    • August 2016
    • July 2016
    • June 2016
    • May 2016
    • April 2016
    • March 2016
    • February 2016
    • January 2016
    • December 2015
    • November 2015
    • October 2015
    • September 2015
    • August 2015
    • July 2015
    • June 2015
    • May 2015
    • April 2015
    • March 2015
    • February 2015
    • January 2015
    • December 2014
    • November 2014
© 2021 Business Intelligence Info
Power BI Training | G Com Solutions Limited